Edition:
United States

GlycoMimetics Inc (GLYC.OQ)

GLYC.OQ on NASDAQ Stock Exchange Global Market

10.76USD
4:00pm EDT
Change (% chg)

$0.24 (+2.28%)
Prev Close
$10.52
Open
$11.13
Day's High
$11.30
Day's Low
$10.71
Volume
200,343
Avg. Vol
132,109
52-wk High
$16.94
52-wk Low
$3.83

Chart for

About

GlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment... (more)

Overall

Beta: 3.06
Market Cap(Mil.): $344.25
Shares Outstanding(Mil.): 32.72
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 89.38 16.52
EPS (TTM): -- -- --
ROI: -- 2.39 11.32
ROE: -- 3.35 15.18

BRIEF-GlycoMimetics says files for mixed shelf of upto $250 mln

* GlycoMimetics Inc says files for mixed shelf of upto $250.0 million - SEC filing‍​ Source text: (http://bit.ly/2xOoKE6) Further company coverage:

Sep 28 2017

BRIEF-GlycoMimetics Inc says to receive European patent for GMI-1271

* GlycomiMetics Inc says to receive European patent for GMI-1271; will have claims directed at GMI-1271 extending at least until 2032 Source text for Eikon: Further company coverage:

Jul 06 2017

BRIEF-Glycomimetics' GMI-1271 receives EU orphan drug designation

* Glycomimetics' GMI-1271 receives EU orphan drug designation for acute myeloid leukemia Source text for Eikon: Further company coverage:

May 25 2017

BRIEF-Glycomimetics announces pricing of public offering of common stock

* Glycomimetics announces pricing of public offering of common stock

May 24 2017

BRIEF-Glycomimetics Inc terminates sales agreement with Cowen and Company

* Glycomimetics Inc - co terminated its sales agreement, dated March 1, 2016, with Cowen and Company Source text for Eikon: (http://bit.ly/2qaOyrv) Further company coverage:

May 24 2017

BRIEF-Glycomimetics announces proposed public offering of common stock

* Glycomimetics announces proposed public offering of common stock

May 22 2017

BRIEF-Glycomimetics reports supportive biomarker data from early-stage trial of GMI-1271

* GlycoMimetics announces high overall response rates, low induction mortality, promising initial survival outcomes, and supportive biomarker data from phase 1/2 trial of GMI-1271 in AML Source text for Eikon: Further company coverage:

May 18 2017

BRIEF-Glycomimetics reports qtrly net loss per share of $0.34

* Glycomimetics reports program updates and first quarter 2017 results

May 08 2017

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $143.62 +1.22
Novartis AG (NOVN.S) CHF85.15 +0.70
Pfizer Inc. (PFE.N) $36.40 -0.02
Merck & Co., Inc. (MRK.N) $63.40 -0.48
Roche Holding Ltd. (ROG.S) CHF234.90 +0.50
Roche Holding Ltd. (RO.S) CHF238.10 +1.20
Bayer AG (BAYGn.DE) €117.25 -0.70
Bayer AG (BAYE.F) -- --

Earnings vs. Estimates